At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
03880 MEDTIDE
Market Closed 08-28 15:59:14
21.500
-0.540
-2.45%
High21.800Low21.100Vol102.90K
Open21.800D1 Closing22.040Amplitude3.18%
Mkt Cap3.05BTradable Cap3.05BTotal Shares141.80M
T/O2.21MT/O Rate0.07%Tradable Shares141.80M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Medtide (SEHK:3880) Stock Drifts As Margin Gains Meet Revenue Reset
Simply Wall St.  ·  08-28 19:33
Medtide (SEHK:3880) Stock Drifts As Margin Gains Meet Revenue Reset
MEDTIDE Proposes Adoption of Restricted Share Unit Scheme
Stock News  ·  08-27 16:52
MEDTIDE Proposes Adoption of Restricted Share Unit Scheme
MEDTIDE Posts 47.4% Drop in Net Profit for Interim Results
Stock News  ·  08-27 16:41
MEDTIDE Posts 47.4% Drop in Net Profit for Interim Results
Medtide Proposes Bylaw Changes to Allow Board Size Range of Five to Nine Directors
Reuters  ·  08-27 16:40
Medtide Proposes Bylaw Changes to Allow Board Size Range of Five to Nine Directors
Medtide Proposes 10-Year RSU Incentive Scheme with 14,180,000-Share Mandate Limit
Reuters  ·  08-27 16:35
Medtide Proposes 10-Year RSU Incentive Scheme with 14,180,000-Share Mandate Limit
Medtide Hy Revenue Rmb234.5 Mln
THOMSON REUTERS  ·  08-27 16:32
Medtide Hy Revenue Rmb234.5 Mln
Medtide H1 FY26 Profit Drops 47.4% to RMB 53.68 Million; Revenue Falls 7.6% to RMB 234.52 Million
Reuters  ·  08-27 16:31
Medtide H1 FY26 Profit Drops 47.4% to RMB 53.68 Million; Revenue Falls 7.6% to RMB 234.52 Million
Precision Peptide Develops Needle-Free Tirzepatide Transdermal Patch in U.S
Reuters  ·  08-19
Precision Peptide Develops Needle-Free Tirzepatide Transdermal Patch in U.S
Medtide Schedules Board Meeting to Review Interim Results
Reuters  ·  08-17
Medtide Schedules Board Meeting to Review Interim Results
Hong Kong Stock CXO Sector Rallies; Will MEDTIDE (03880) Defy the Trend or Bounce Back After Its Profit Warning?
Stock News  ·  08-07
Hong Kong Stock CXO Sector Rallies; Will MEDTIDE (03880) Defy the Trend or Bounce Back After Its Profit Warning?
Cpc Scientific Announces U.S. FDA Pre-License Inspection (Pli) Successfully Completed at Its Hangzhou Cgmp Manufacturing Facility for Hepcludex® API, Establishing a Proven Track Record Under the Stringent Bla Pathway
THOMSON REUTERS  ·  08-05
Cpc Scientific Announces U.S. FDA Pre-License Inspection (Pli) Successfully Completed at Its Hangzhou Cgmp Manufacturing Facility for Hepcludex® API, Establishing a Proven Track Record Under the Stringent Bla Pathway
Medtide Posts Steady July 2026 Share Capital; Public Float Remains Compliant
Bulletin Express  ·  08-05
Medtide Posts Steady July 2026 Share Capital; Public Float Remains Compliant
Medtide completes U.S. FDA Pre-License Inspection for Hepcludex API at Hangzhou facility
Bulletin Express  ·  07-31
Medtide completes U.S. FDA Pre-License Inspection for Hepcludex API at Hangzhou facility
MEDTIDE (03880) Issues Profit Warning, Expects First-Half Profit to Drop Approximately 44% to 51.6% Year-on-Year
Stock News  ·  07-31
MEDTIDE (03880) Issues Profit Warning, Expects First-Half Profit to Drop Approximately 44% to 51.6% Year-on-Year
MEDTIDE's HEPCLUDEX® Active Ingredient Passes FDA Pre-License Inspection
Stock News  ·  07-31
MEDTIDE's HEPCLUDEX® Active Ingredient Passes FDA Pre-License Inspection
MEDTIDE Appoints New CFO and Revamps Key Management Positions
Stock News  ·  07-31
MEDTIDE Appoints New CFO and Revamps Key Management Positions
Medtide Unit Chinese Peptide Completes US FDA Pre-license Inspection for Hepcludex API Facility
Reuters  ·  07-31
Medtide Unit Chinese Peptide Completes US FDA Pre-license Inspection for Hepcludex API Facility
Medtide Names Ding Lijun as CFO
Reuters  ·  07-31
Medtide Names Ding Lijun as CFO
Medtide - Subsidiary Completes U.S. FDA Pre-License Inspection at Hangzhou Facility
THOMSON REUTERS  ·  07-31
Medtide - Subsidiary Completes U.S. FDA Pre-License Inspection at Hangzhou Facility
Medtide Expects H1 Profit to Fall 44%-52% to RMB 49.4 million-RMB 57.1 Million
Reuters  ·  07-31
Medtide Expects H1 Profit to Fall 44%-52% to RMB 49.4 million-RMB 57.1 Million

Introduction

Company Name.
MEDTIDE
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Medtide Inc is a China-based company mainly engaged in the contract research, development and manufacturing of peptide. The Company mainly provides contract research organization (CRO) services, namely peptide new chemical entity (NCE) discovery synthesis, contract development and manufacturing organization (CDMO) services, namely peptide chemistry, manufacturing, and control (CMC) development and commercial manufacturing. The Company's services primarily focus on providing customers with active pharmaceutical ingredients (APIs) rather than drug products. The Company also provides customers with peptide drug development, production, and CMC filing support services. The Company mainly operates its business in the domestic market and overseas markets.
Issue price:
--